ARRB1 and plasma cell myeloma: This preservation of splenic architecture and significantly lower CD138+ myeloma cells in ARRB1-deficient hosts suggests reduced tumor burden and/or altered immune cell trafficking, consistent with enhanced anti-tumor immunity.